No Data
No Data
Express News | PPBT Stock Has Given up Its Prior Gain. Purple Biotech Shares Were Trading Higher After the Company's CM24 Showed up to a 90% Reduction in the Death Risk for Pancreatic Cancer Patients and Announced It Will Commence a Phase 2b Study
Purple Biotech Announces Significant Efficacy Results From Phase 2 CM24 Study
Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study
Purple Biotech Reports Promising Biomarker Data for NT219 in Colorectal Cancer and Head and Neck Cancer at AACR 2025 Annual Meeting
Purple Biotech Announces Publication of Study on Potential of NT219
Express News | Purple Biotech Announced Today The Publication Of An Independent Study Titled "IRS2 As A Driver Of Brain Metastasis In Colorectal Cancer: A Potential Target For Novel Therapeutic Strategies" In The Peer Reviewed Journal